Dana-Farber Cancer Institute to create Chen-Huang Center for EGFR Mutant Lung Cancers
The study, published in Nature Biotechnology , developed open-source software that can be used to judge the accuracy of computer predictions and establish this benchmark.
The team developed a simulation framework and scoring system to determine how accurately each algorithm predicted various measures of genetic diversity. These included: the proportion of cancerous cells in the tumor sample; the number of genetically different groups of cancerous cells in the tumor sample; the proportion of cells within each of these groups; which genetic mutations were in each group; and the genetic relationship between the groups.
Our new framework provides a foundation which, over time as it is run against more tumors, will hopefully become a much-needed, unbiased, gold-standard benchmarking tool for assessing models that aim to characterize a tumor's genetic diversity,"
Maxime Tarabichi, joint-lead author, postdoc in the Cancer Genomics Laboratory at the Crick.
The researchers built upon an existing computer software to generate and analyze the 580 predictions in this research, adding new features to the software to create more realistic tumors. This tumor-simulation software and the marking framework are publicly available for other researchers to use either directly or to help develop their own scoring framework.
Computer simulations in cancer genomics are helping us develop more accurate tools, as we understand where these tools perform well, and where they need improvement. Further developing these tools, so they more closely match real-life tumors, should ultimately help clinicians better match patients with personalized medicines." Peter Van Loo, author, group leader in the Cancer Genomics Laboratory at the Crick Source:
The Francis Crick Institute Journal reference:
Salcedo, A., et al. (2020) A community effort to create standards for evaluating tumor subclonal reconstruction. Nature Biotechnology . doi.org/10.1038/s41587-019-0364-z .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology